

QUARTERLY FINANCIAL INFORMATION AT 31 MARCH 2009

(NOT AUDITED)

SOLID GROWTH

IN LINE WITH THE FY 2009 TARGET OF €900 MILLION

Paris, May 15, 2009 – Cegedim, the world's leading CRM provider for the pharmaceutical industry, generated consolidated revenues of €209 million in the first quarter of 2009, an 11% increase like-for-like* compared with Q1 2008 and a 10% increase on a reported basis.

The positive impact of Dendrite's acquisition, an ideally positioned offering covering every segment of the market, the strength of the Cegedim Dendrite brand in the field of CRM, the diversity of businesses and the good geographical balance of revenues are vital assets, and the company has been able to take advantage of them.

€ millions	Q1	Q1	Change Q1 09 / Q1 08	
	2009	2008	Reported	L-f-L*
CRM and strategic data	115,568	115,764	-0.2 %	-1.3 %
Healthcare professionals	66,137	48,684	+35.9 %	+41.1 %
Insurances and services	26,957	25,379	+6.6 %	+6.2 %
Group	208,662	189,827	+9.9 %	+10.7 %

* at constant scope and exchange rates

Q1 2009 revenues reflect the following factors:

- The effects of the external growth policy and the divestment of a portion of the marketing business in the US.
- The negligible currency impact on revenues due to the good geographic balance among the Group's businesses. In this case, the euro's appreciation against the pound sterling was offset by the yen's gains against the euro.

Geographic breakdown of revenues by currency

%	Euro €	Pound Sterling £	Europe ex. £ and €	US Dollar \$	Row
CRM and strategic data	50 %	4 %	8 %	25 %	13 %
Healthcare professionals	78 %	22 %	0 %	0 %	0 %
Insurances and services	99.8 %	0 %	0.2 %	0 %	0 %
Group	65 %	9 %	4 %	14 %	7 %

CRM and strategic data

Q1 2009 revenues came to €116 million, a 1.3% drop like-for-like* and stable like-for-like. This performance reflects the following factors:

- The US subsidiary recorded a notable performance considering present conditions; the Group continues to gain market share in the CRM business.
- The Group is fully benefiting from the high level of recurrent sales with pharmaceutical companies.
- Conversely, given current economic conditions, some clients have decided to postpone ordering “strategic data”. The Group remains very confident that orders will bounce back in the months ahead.
- Currencies effects have a positive impact of 2.5% on *CRM and strategic data* revenues, mainly because of the dollar and the yen’s gains against the euro, which were partly offset by the euro’s appreciation against the pound sterling.

Healthcare professionals

Q1 2009 revenues came to €66 million, a 41.1% increase like-for-like* and a 35.9% increase on a reported basis. This performance reflects the following factors:

- The excellent growth momentum continues at the business that publishes software for doctors and paramedics, notably in the UK, resulting in double-digit growth.
- Cegelease’s financial lease activities benefited from an undemanding year-on-year comparison and contributed heavily to this sector’s growth.
- Currencies effects have a negative impact of 5.2% on *Healthcare professionals* revenues, due notably to the euro’s gains against the pound sterling.

Insurances and services

Q1 2009 revenues came to €27 million, a 6.6% like-for-like increase* and a 6.2% increase on a reported basis. This performance reflects the following factors:

- Brisk business in computerization of public and private health insurers and managing payment flows.
- Double-digit growth at Cegedim SRH (outsourced payroll and human resources management).
- As a reminder, currencies effects on *Insurances and services* are insignificant because the vast majority of its business is in France.

Important events and transactions in Q1 2009

Looking to strengthen its selective investment strategy, the Group acquired a publisher of software for pharmacists in Tunisia and a database in Belgium. These acquisitions were self-financed and represent a total full fiscal year revenues of €0.5 million.

Pursuant to the terms of the agreements, the details of these transactions are confidential.

Financial position

Cegedim's key ratios show that its financial situation is under control. The Group had a confirmed undrawn €60 million line of credit at mid-May and is generating cash flow in line with its targets. As a result, it is comfortable that it will be able to meet its upcoming partial debt repayment obligations of €29.5 million and \$17 million twice yearly starting June 30, 2009.

2009 outlook

As stated in April, Cegedim is still on track and is maintaining its 2009 target of 6% revenue growth to €900 million.

In addition, all of the cost-cutting measures implemented in 2008 are likely to have a positive impact on margins, all other things being equal.

Calendar

May 27, 2009: Shareholders' meeting

August 12, 2009 after the stock market closing: First-half 2009 revenues announcement

About Cegedim:

Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, pharmaceutical companies, healthcare professionals and insurance companies.

The world leader in pharmaceutical CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs more than 8,200 people in 80 countries and generated revenue of €849 million in 2008. To learn more, please visit our website: www.cegedim.com

Listed on NYSE Euronext Paris, compartment B – ISIN FR0000053506 – Reuters CGDM.PA – Bloomberg CGM

Media inquiries

Cegedim
Aude Balleydier
Media Relations
Tel. : +33 (0)1 49 09 68 81
aude.balleydier@cegedim.fr

Presse & Papiers Agency
Guillaume de Chamisso
Press Officer
Tel: + 33 (0)1 77 35 60 99
guillaume.dechamisso@pressepapiers.fr

Investor relations

Cegedim
Jan Eryk Umiastowski
Chief Investments Officer – Chief Investors Relations
Tel. : +33 (0)1 49 09 33 36
investor.relations@cegedim.fr